To corroborate the hypothesis that the employment of PET with PSMA-targeting radiopharmaceuticals might play a role in TC patients’ management, several case reports and retrospective studies reported a low incidence of thyroid incidentalomas in patients undergoing PSMA-targeted PET/CT for other purposes (generally prostate cancer restaging) [29,30]. This evidence concerns the gene FOLH1 and prostate cancer.